TiGenix: Appoints Gri-Cel CEO Dirk Buscher And COO Jose Terencio To Board Of Directors Following Strategic Investment By Grifols

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEUVEN, Belgium, Dec. 5, 2013 (GLOBE NEWSWIRE) -- TiGenix (Euronext Brussels: TIG) announced today that it has appointed Dirk Büscher and José Terencio to the Company's board of directors, in replacement of Nico Vandervelpen (LRM Beheer NV) and Joël Jean-Mairet (Ysios Capital Partners SGEGR SA), who resigned from the board. The appointments follow the recent EUR 12 million investment by Gri-Cel SA in TiGenix. Gri-Cel is a fully-owned subsidiary of Grifols, a world leader in plasma-derived therapeutics.

Help employers find you! Check out all the jobs and post your resume.

Back to news